RG
SYRS

Redmile Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Redmile Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,891
Closed -$174K – 78
2021
Q3 		$174K Hold
3,891
– – ﹤0.01% 74
2021
Q2 		$212K Sell
3,891
-17,338
-82% -$1.03M ﹤0.01% 85
2021
Q1 		$1.59M Hold
21,229
– – 0.02% 82
2020
Q4 		$2.3M Hold
21,229
– – 0.03% 83
2020
Q3 		$1.88M Hold
21,229
– – 0.03% 75
2020
Q2 		$2.26M Hold
21,229
– – 0.04% 76
2020
Q1 		$1.26M Hold
21,229
– – 0.04% 63
2019
Q4 		$1.47M Sell
21,229
-367,646
-95% -$22.3M 0.04% 61
2019
Q3 		$40.4M Buy
388,875
+26,837
+7% +$2.53M 1.35% 22
2019
Q2 		$33.5M Buy
362,038
+197,518
+120% +$13.8M 0.95% 32
2019
Q1 		$15M Sell
164,520
-434
-0.3% -$30.2K 0.44% 50
2018
Q4 		$9.19M Sell
164,954
-660
-0.4% -$50.1K 0.37% 52
2018
Q3 		$19.7M Buy
165,614
+2,490
+2% +$289K 0.61% 53
2018
Q2 		$16.7M Sell
163,124
-2,100
-1% -$260K 0.57% 47
2018
Q1 		$21.4M Buy
165,224
+101,501
+159% +$11.1M 0.83% 37
2017
Q4 		$6.2M Sell
63,723
-419
-0.7% -$56.3K 0.27% 55
2017
Q3 		$9.44M Sell
64,142
-33,184
-34% -$6.24M 0.47% 46
2017
Q2 		$15.7M Buy
97,326
+2,052
+2% +$322K 0.95% 39
2017
Q1 		$15.2M Buy
95,274
+430
+0.5% +$52.5K 0.99% 40
2016
Q4 		$11.5M Buy
94,844
+5,566
+6% +$780K 0.99% 28
2016
Q3 		$11.7M Sell
89,278
-5,340
-6% -$678K 0.93% 29
2016
Q2 		$15.1M Buy
+94,618
New +$17.2M 1.44% 26

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group's SYRS Position: Q4 2021 in Review

Redmile Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 3,891 shares — an estimated $174K sold.

Redmile Group first reported a position in SYRS in Q2 2016 and held it in 22 quarters. The position peaked at $40.4M in Q3 2019. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

  • Redmile Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Redmile Group sold 3,891 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $174K.
  • Redmile Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 22 quarters.
  • Redmile Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $40.4M in Q3 2019.
  • 90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.